Oppenheimer & Co’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Oppenheimer & Co’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,055	Closed	-$221K	–	1527
2021 Q4	$221K	Sell	5,055 -65	-1%	-$3.08K	﹤0.01%	1358
2021 Q3	$260K	Buy	5,120 +100	+2%	+$5.21K	﹤0.01%	1279
2021 Q2	$261K	Buy	+5,020	New	+$236K	﹤0.01%	1310

Other funds holding IDNA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Oppenheimer & Co's IDNA Position: Q1 2022 in Review

Oppenheimer & Co sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 5,055 shares — an estimated $221K sold.

Oppenheimer & Co first reported a position in IDNA in Q2 2021 and held it in 3 quarters. The position peaked at $261K in Q2 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.

Oppenheimer & Co reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
Oppenheimer & Co sold 5,055 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $221K.
Oppenheimer & Co first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2021 and held it in 3 quarters.
Oppenheimer & Co's iShares Genomics Immunology and Healthcare ETF position peaked at $261K in Q2 2021.
86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.